Sanofi invests $8 billion to replace Dupixent blockbuster

Sanofi and Regeneron are investing up to $8 billion to develop antibodies similar to Dupixent.

Published 6sem3 sources✓ ConfirmedNotableupdated 6sem
Lire en français
≈ 20s

The fact

The drug, which will lose exclusivity in the early 2030s, generated €15.7 billion in revenue for Sanofi.

This strategy aims to secure the group’s income amid generic competition.

3 sources — click a link to read an article on the topic:
Explore this topic
What if you saw the whole news differently?Factae cross-checks hundreds of sources worldwide to keep only the fact, no opinion. Explore the front page.
France · © OpenStreetMap, OpenMapTiles, OpenFreeMapWorld map →
Follow topic →
Auto-synthesis from 3 media sources · identified on October 1, 2026
← Back to home
Discover

Read more

All economie →